oncolytics biotech is a biotechnology company focused on the development of oncolytic viruses as potential therapeutics for use in a broad range of cancers. the company is conducting clinical studies using reolysin®, its proprietary formulation of the human reovirus, in some of the most prevalent forms of the disease including lung, colorectal and pancreatic cancers. oncolytics’ clinical program includes a number of human trials at a variety of stages including a phase iii trial in head and neck cancers. the company has advanced its product manufacturing and intellectual property initiatives in parallel with its clinical development program to support development of a commercial product.
Company profile
Ticker
ONCY
Exchange
Website
CEO
Matthew C. Coffey
Employees
Location
Fiscal year end
Industry (SIC)
SEC CIK
ONCY stock data
Latest filings (excl ownership)
20-F
2023 FY
Annual report (foreign)
12 Mar 24
6-K
Oncolytics Biotech® Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
7 Mar 24
6-K
Oncolytics Biotech® Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN
5 Mar 24
6-K
Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights
4 Mar 24
6-K
Oncolytics Biotech® Announces Presentation at the Cancer Advocacy Group of Louisiana’s 3rd Annual NeauxCancer Conference
28 Feb 24
6-K
Current report (foreign)
14 Feb 24
6-K
Oncolytics Biotech® Appoints Patricia S. Andrews to its Board of Directors
9 Jan 24
6-K
Oncolytics Biotech® Recaps 2023 Accomplishments, Provides Outlook for 2024
4 Jan 24
6-K
Oncolytics Biotech® and SOLTI Present Positive Translational Data at SABCS
7 Dec 23
6-K
Oncolytics Announces the Anal Cancer Cohort of the GOBLET Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for Efficacy
9 Nov 23
Transcripts
ONCY
Earnings call transcript
2022 Q2
11 Aug 22
ONCY
Earnings call transcript
2022 Q1
6 May 22
ONCY
Earnings call transcript
2021 Q4
4 Mar 22
ONCY
Earnings call transcript
2021 Q3
5 Nov 21
ONCY
Earnings call transcript
2021 Q2
6 Aug 21
ONCY
Earnings call transcript
2020 Q4
5 Mar 21
ONCY
Earnings call transcript
2020 Q3
11 Nov 20
Latest ownership filings
No filings
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q2 2023
1.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 30 |
Opened positions | 6 |
Closed positions | 5 |
Increased positions | 8 |
Reduced positions | 5 |
13F shares | Current |
---|---|
Total value | 1.91 bn |
Total shares | 810.88 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
International Assets Investment Management | 194.96 k | $506.90 mm |
MS Morgan Stanley | 184.21 k | $478.95 mm |
BNP Paribas Arbitrage | 68.32 k | $177.63 mm |
CIBC World Markets | 60.91 k | $161.00 k |
RY Royal Bank Of Canada | 53.21 k | $138.00 mm |
Long Focus Capital Management | 40.00 k | $104.00 mm |
Geode Capital Management | 34.66 k | $90.11 mm |
Dimensional Fund Advisors | 33.49 k | $87.06 mm |
BMO Bank of Montreal | 32.38 k | $85.29 mm |
Newman Dignan & Sheerar | 18.92 k | $49.18 mm |
News
HC Wainwright & Co. Maintains Buy on Oncolytics Biotech, Maintains $5 Price Target
8 Mar 24
Recap: Oncolytics Biotech Q4 Earnings
7 Mar 24
Earnings Scheduled For March 7, 2024
7 Mar 24
A Preview Of Oncolytics Biotech's Earnings
6 Mar 24
HC Wainwright & Co. Reiterates Buy on Oncolytics Biotech, Maintains $5 Price Target
14 Feb 24
Press releases
Biotech's Role in Addressing the Pancreatic Cancer Emergency
14 Mar 24
Oncolytics Biotech® Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
7 Mar 24
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
5 Mar 24
Oncolytics Biotech® Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN
5 Mar 24
Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights
4 Mar 24